TrialOncology2025

Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.

Michael LaPelusa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.